Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator-Activated Receptor-γ Agonist in Hypercholesterolemia

Circulation

Volumn 108, Issue 22, 2003, Pages 2805-2811

  Tao, Ling ^a   Liu, Hui Rong ^a   Gao, Erhe ^a   Teng, Zhi Ping ^a   Lopez, Bernard L ^a   Christopher, Theodore A ^a   Ma, Xin Liang ^a   Batinic Haberle, Ines ^b   Willette, Robert N ^c   Ohlstein, Eliot H ^c   Yue, Tian Li ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Atherosclerosis; Endothelium; Hypercholesterolemia; Inflammation

Indexed keywords

3 NITROTYROSINE; CHOLESTEROL; GLYCOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; ROSIGLITAZONE; SUPEROXIDE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINITRATIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CAROTID ARTERY; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG MECHANISM; HYPERCHOLESTEROLEMIA; LEUKOCYTOSIS; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RABBIT; SIGNAL TRANSDUCTION; VASCULOPROTECTIVE ACTIVITY; VASODILATATION;

ANIMALS; ANTIOXIDANTS; BLOOD VESSELS; CAROTID ARTERIES; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; NITRATES; NITRIC OXIDE; NITRITES; RABBITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TYROSINE; VASODILATION;

EID: 10744223422     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000097003.49585.5E     Document Type: Article

References (31)

1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
2. Oelze M, Mollnau H, Hoffmann N, et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res. 2000; 87:999-1005.
3. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823-834.
4. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003;52:173-180.
5. Hsueh WA, Law RE. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol. 2001;21:1891-1895.
6. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep. 2000;2:327-335.
7. Ma XL, Gao F, Chen J, et al. Endothelial protective and antishock effects of a selective estrogen receptor modulator in rats. Am J Physiol. 2001; 280:H876-H884.
8. Lund DD, Faraci FM, Miller FJ Jr, et al. Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits. Circulation. 2000;101:1027-1033.
9. Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 2002;105:1497-1502.
10. Gao F, Yao CL, Gao EH, et al. Enhancement of glutathione cardioprotection by ascorbic acid in myocardial reperfusion injury. J Pharmacol Exp Ther. 2002;301:1-8.
11. Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res. 2003;92: 1162-1169.
12. Park KS, Ciaraldi TP, Lindgren K, et al. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab. 1998;83:2830-2835.
13. Su JL, Winegar DA, Wisely GB, et al. Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro. Hybridoma. 1999;18:273-280.
14. Gambaryan S, Hauser W, Kobsar A, et al. Distribution, cellular localization, and postnatal development of VASP and Mena expression in mouse tissues. Histochem Cell Biol. 2001;116:535-543.
15. Mulsch A, Oelze M, Kloss S, et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation. 2001;103:2188-2194.
16. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58-E65.
17. Warnholtz A, Mollnau H, Heitzer T, et al. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol. 2002;40:1356-1363.
18. Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of NOx family proteins in human atherosclerosis. Circulation. 2002;105:1429-1435.
19. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105: 1656-1662.
20. Warnholtz, A, Nickenig G, Schulz E, et al. Increased NADH-oxidase mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
21. Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res. 2001;44:345-352.
22. Kelly DP. PPARs of the heart: three is a crowd. Circ Res. 2003;92: 482-484.
23. Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and a-tocopherol (vitamin E). Circ Res. 2000;87: 349-354.
24. Ma XL, Yue TL, Lopez BL, et al. Carvedilol, a new beta-adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther. 1996;277:128-136.
25. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001;50:3-11.
26. Ramachandran A, Levonen AL, Brookes PS, et al. Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radic Biol Med. 2002;33: 1465-1474.
27. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238.
28. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol. 2000;20:4699-4707.
29. Petrova TV, Akama KT, Van Eldik LJ. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-delta12,14-prostaglandin J2. Proc Natl Acad Sci USA. 1999;96:4668-4673.
30. Linscheid P, Keller U, Blau N, et al. Diminished production of nitric oxide synthase cofactor tetrahydrobiopterin by rosiglitazone in adipocytes. Biochem Pharmacol. 2003;65:593-598.
31. Vinten-Johansen J, Zhao ZQ, Nakamura M, et al. Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Ann N Y Acad Sci. 1999;874:354-370.